Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

June 2025

Amplicon-based NGS panels in clinical practice: From broad oncology applications to advancing breast cancer care-June 17, 2025


Webinar presenters Emilie Lalonde, PhD, FACMG, Molecular Geneticist and Cytogeneticist, Molecular Diagnostics Division, PaLM, London Health Sciences Centre and St. Joseph’s Health Care, Assistant Professor, Pathology and Laboratory Medicine, Western University, and Cheryl A. Mather, MD Medical Director, Molecular Pathology (North Sector), Alberta Precision Laboratories, Assistant Clinical Professor, Department of Laboratory Medicine & Pathology, University of Alberta, discuss how amplicon-based NGS panels meet biomarker testing guidelines in practice including routine diagnostics, expanded workup, and copy number variation (CNV) detection.

Clinical pathology selected abstracts

June 2025—Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist medication that has FDA approval for treating diabetes and obesity and that has shown exceptional efficacy. A rapid increase in use of this drug has been accompanied by reports of reduced alcohol use and cravings during semaglutide treatment. Alcohol use is a leading modifiable cause of morbidity and mortality and accounts for four to five percent of disease burden and 2.6 million deaths per year globally. Alcohol is also associated with increased risk of common diseases, including cardiovascular and liver disease and cancers. It is estimated that approximately 29 and 11 percent of U.S. adults meet lifetime and past-year criteria for alcohol use disorder (AUD), respectively.

Anatomic pathology selected abstracts

June 2025—Transbronchial cryobiopsies are increasingly used to diagnose interstitial lung disease, but published information on the features of specific manifestations of ILD in cryobiopsies is lacking. Therefore, the authors sought to provide pathologic guidelines for separating usual interstitial pneumonia (UIP) of idiopathic pulmonary fibrosis (IPF), fibrotic hypersensitivity pneumonitis (FHP), and connective tissue disease-associated interstitial lung disease (CTD-ILD) in cryobiopsies. They examined 120 cryobiopsies from patients with CTD-ILD established via multidisciplinary discussion and compared them with a prior series of 121 biopsies from patients with IPF or FHP also established via multidisciplinary discussion. A nonspecific interstitial pneumonia (NSIP) pattern alone was seen in 36 of 120 (30 percent) CTD-ILD, three of 83 (3.6 percent) FHP, and two of 38 (5.2 percent) IPF cases, statistically favoring a diagnosis of CTD-ILD.

Molecular pathology selected abstracts

June 2025—Comprehensive molecular profiling and DNA methylation classification have become critical for diagnosing and managing central nervous system tumors. However, workflows for molecular testing of these tumors are often limited by the cost of equipment and reagents, technical complexity, and lengthy turnaround times. The wide range of alterations that can be present, including MGMT promoter methylation, single nucleotide variants, insertions or deletions (indels), copy number variants, and fusions and structural variants, often necessitate the use of multiple assays for a complete molecular workup. All of these factors have led to a growing demand for molecular assays that are faster, more comprehensive, and more accessible. Recognizing this need, the authors had previously conducted a proof-of-concept study of an adaptive sampling-based nanopore sequencing workflow platform, called Rapid-CNS2, that they had developed.

Newsbytes

June 2025—Whether it’s easier to edit a document created by another source or create more or less the same document from scratch is open to debate. But clinical informaticians at Stanford Health Care, Palo Alto, Calif., are banking on clinicians preferring to assess and adjust versus starting with a blank page. Therefore, the health care system has been conducting trials on the use of generative artificial intelligence to draft patient-centric interpretations of pathology test results that these care providers can review and edit and then share with patients.

Q&A column

June 2025
Q. Our institution performs rapid onsite evaluation (ROSE). In cases in which multiple passes are done, we frequently encounter unsatisfactory specimens (debris, neutrophils, bronchial cells, etc.). These cases are rescreened by a cytotechnologist and pathologist. If the case goes to a different pathologist, those unsatisfactory slides are unnecessarily screened three times. They’re also included in the daily slide workload of the cytotechnologist. Can the onsite pathologist dispose of unsatisfactory Diff-Quik slides and keep just the counter formalin-fixed slides? Since ROSE is provided for that episode, can you comment on billing? Read answer.

Q. Many times a platelet count on an automated hematology system indicates some degree of thrombocytopenia or the analyzer reports a high mean platelet volume or platelet large cell ratio, while a blood smear shows large platelets and/or giant platelets. Is it OK to include a comment in the report that the platelets are adequate or that the count could be due to large platelets, especially with values that indicate marked thrombocytopenia? Read answer.

Put It on the Board

June 2025—A Labcorp survey of more than 100 genetic counselors, including 15 hours of one-one-one conversations, found their three pain points to be balancing patient care and administrative demands, the financial difficulties that complex genetic testing presents, and staying on top of scientific and technologic advances in genetics. Of the time constraints, one genetic counselor at a large health system said, “Anything a lab partner can do, from making their portal easier to get reports or having easy access to someone on their end to help me with some questions, all that gives me more time with the patient.”

Letters

June 2025—I was encouraged to read the CAP TODAY articles on DPYD testing (“Time for wider pretreatment DPYD genotyping?” December 2024; “DPYD genotyping assays—what’s recommended and why,” January 2025). I lost my mother not to her cancer but to a known and preventable toxicity from 5-fluorouracil (5-FU) chemotherapy. She was never informed of the risks of 5-FU if one is DPD deficient nor was she tested for DPD deficiency, a genetic condition that impairs the body’s ability to break down 5-FU and capecitabine. Within days of starting treatment, she developed devastating toxicity that ultimately took her life. We had no warning. Only after she was suffering in the hospital from 5-FU toxicity did I learn about DPYD testing, which could have spared her horrific pain and saved her life. My mom was so easy to live with and so hard to live without. We continue to be heartbroken that her golden years were cut short.

MARKETPLACE

TRENDING